Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.

Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG.

J Diabetes Complications. 2017 Nov;31(11):1630-1637. doi: 10.1016/j.jdiacomp.2017.07.014. Epub 2017 Jul 31. Review.

PMID:
28886991
2.

Practical management of the increasing burden of non-alcoholic fatty liver disease.

Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA.

Frontline Gastroenterol. 2010 Oct;1(3):149-155. doi: 10.1136/fg.2009.000935. Epub 2010 Sep 23. Review.

3.

Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.

Stengel JZ, Harrison SA.

Gastroenterol Hepatol (N Y). 2006 Jun;2(6):440-449.

4.

Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).

Chen Q, Wang T, Li J, Wang S, Qiu F, Yu H, Zhang Y, Wang T.

Nutrients. 2017 Jan 31;9(2). pii: E96. doi: 10.3390/nu9020096. Review.

5.

Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, Kong R, Li L, Li J, Feng J, Wu L, Liu T, Xia Y, Lu J, Guo C, Zhou Y.

Gastroenterol Res Pract. 2017;2017:8491742. doi: 10.1155/2017/8491742. Epub 2017 Jan 4.

6.

Dapagliflozin-Induced Acute-on-Chronic Liver Injury.

Levine JA, Ann Lo A, Wallia A, Rogers M, VanWagner LB.

ACG Case Rep J. 2016 Dec 7;3(4):e169. doi: 10.14309/crj.2016.142. eCollection 2016 Aug.

8.

Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.

Dajani A, AbuHammour A.

Saudi J Gastroenterol. 2016 Mar-Apr;22(2):91-105. doi: 10.4103/1319-3767.178527. Review.

9.

Pharmacotherapy for Nonalcoholic Fatty Liver Disease.

Gawrieh S, Chalasani N.

Semin Liver Dis. 2015 Aug;35(3):338-48. doi: 10.1055/s-0035-1562951. Epub 2015 Sep 17. Review.

10.

Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Spengler EK, Loomba R.

Mayo Clin Proc. 2015 Sep;90(9):1233-46. doi: 10.1016/j.mayocp.2015.06.013. Epub 2015 Jul 26. Review.

11.

Non-alcohol fatty liver disease in Asia: Prevention and planning.

Ashtari S, Pourhoseingholi MA, Zali MR.

World J Hepatol. 2015 Jul 8;7(13):1788-96. doi: 10.4254/wjh.v7.i13.1788.

12.

Systematic review: Preventive and therapeutic applications of metformin in liver disease.

Bhat A, Sebastiani G, Bhat M.

World J Hepatol. 2015 Jun 28;7(12):1652-9. doi: 10.4254/wjh.v7.i12.1652. Review.

13.

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.

Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ.

Diabetes. 2015 Sep;64(9):3305-13. doi: 10.2337/db14-1947. Epub 2015 May 27.

14.

Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.

Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R.

J Clin Exp Hepatol. 2015 Mar;5(1):51-68. doi: 10.1016/j.jceh.2015.02.006. Epub 2015 Mar 6. Review.

15.

Non-alcoholic fatty liver disease: The diagnosis and management.

Abd El-Kader SM, El-Den Ashmawy EM.

World J Hepatol. 2015 Apr 28;7(6):846-58. doi: 10.4254/wjh.v7.i6.846. Review.

16.

Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome.

Tan S, Vollmar N, Benson S, Sowa JP, Bechmann LP, Gerken G, Fuhrer D, Canbay A.

Int J Endocrinol. 2015;2015:254169. doi: 10.1155/2015/254169. Epub 2015 Mar 19.

17.

Treatment of nonalcoholic steatohepatitis in adults: present and future.

Gitto S, Vitale G, Villa E, Andreone P.

Gastroenterol Res Pract. 2015;2015:732870. doi: 10.1155/2015/732870. Epub 2015 Mar 18. Review.

18.

Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.

Kwan HY, Niu X, Dai W, Tong T, Chao X, Su T, Chan CL, Lee KC, Fu X, Yi H, Yu H, Li T, Tse AK, Fong WF, Pan SY, Lu A, Yu ZL.

Sci Rep. 2015 Mar 13;5:9114. doi: 10.1038/srep09114.

19.

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

Le TA, Loomba R.

J Clin Exp Hepatol. 2012 Jun;2(2):156-73. doi: 10.1016/S0973-6883(12)60104-2. Epub 2012 Jul 21.

20.

Metformin and metabolic diseases: a focus on hepatic aspects.

Zheng J, Woo SL, Hu X, Botchlett R, Chen L, Huo Y, Wu C.

Front Med. 2015 Jun;9(2):173-86. doi: 10.1007/s11684-015-0384-0. Epub 2015 Feb 12. Review.

Supplemental Content

Support Center